GlaxoSmithKline Australia Pty Ltd.

04/21/2017 | Press release | Distributed by Public on 04/20/2017 20:33

Notice of discontinuation of CERVARIX® (Human Papillomavirus vaccine (Types 16, 18 (Recombinant, AS04 adjuvanted)) supply in Australia

Notice of discontinuation of CERVARIX (Human Papillomavirus vaccine (Types 16, 18 (Recombinant, AS04 adjuvanted)) supply in Australia

GlaxoSmithKline (GSK) has made the decision to stop supplying Cervarixto Australia. GSK is not withdrawing its licence from the Therapeutic Goods Administration (TGA) and will maintain the licence in the event of a supply shortage or other need for the product.

Vaccination against HPV remains available by means of an alternate vaccine supplied through the National Immunisation Program and in the private market.

Existing supply of Cervarix will be available to Australian customers until early 2018, however stock will expire 31 May 2018. It is important to ensure that the dosing schedule is complete in advance of this date.

For information regarding the Cervarix dosing schedule please refer to the Approved Product Information. The Approved Product Information and Consumer Medicine Information (CMI) are available on the TGA website and via the GSK website

GSK continues to sponsor and support clinical trials of Cervarix. A register of ongoing and completed Cervarix trials can be found at the GSK Clinical Study Registry: and at

Should you require any additional information, please contact GSK Medical Information on 1800 033 109.